Clearside Biomedical Appoints Veteran Supply Chain Executive, Thomas Crawford, as Vice President, Supply Chain
October 19 2018 - 8:00AM
Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical
company dedicated to developing treatments that restore and
preserve vision for people with serious eye diseases, today
announced the appointment of Thomas Crawford, CSCP, as Vice
President, Supply Chain.
Mr. Crawford will be responsible for
establishing and managing Clearside’s global supply chain for
clinical testing, training and, if approved, trade distribution of
suprachoroidal CLS-TA, the company’s proprietary suspension of the
corticosteroid triamcinolone acetonide formulated for
administration to the back of the eye via the suprachoroidal
space.
In a career spanning more than 25 years, Mr.
Crawford has extensive expertise in supply chain management, trade
relations, product launches, and manufacturing operations.
Before joining Clearside, he was Vice President of Supply Chain and
Customer Service for Pharma Tech Industries, LLC, the world’s
largest pharmaceutical contract manufacturer and packager of powder
products. Mr. Crawford’s earlier experience includes supply
chain, manufacturing and trade relations management roles at
various pharmaceutical and medical device companies, including
Shionogi Inc., Immucor Inc., Aronex Pharmaceuticals Inc., Allergan,
Inc., Abbot Laboratories and Zenith Goldline Pharmaceuticals,
Inc.
“Thomas brings an important depth of
manufacturing operations and supply chain management experience to
the company,” said Clearside’s Chief Executive Officer and
President, Daniel White. “Thomas will be in a position to
provide seamless distribution management for suprachoroidal CLS-TA
to many of our global testing sites and, if suprachoroidal CLS-TA
is approved, in support of our commercial supply.”
About Clearside
Clearside Biomedical, Inc. is a
biopharmaceutical company dedicated to developing treatments that
restore and preserve vision for people with serious eye
diseases. Clearside’s proprietary suprachoroidal treatment
approach offers unprecedented access to the back of the eye where
sight-threatening disease often occurs. The company’s unique
platform for eye disease treatments is inherently flexible and
intended to work with established medicines, new formulations of
medicines, as well as future innovations. Clearside’s
pipeline includes advanced and pre-clinical product candidates in
diseases where macular edema is a common complication, including
uveitis, retinal vein occlusion (“RVO”) and diabetic macular edema
(“DME”). Clearside’s most advanced program is in
non-infectious uveitis and it expects to submit a New Drug
Application (“NDA”) to the U.S. Food and Drug Administration
(“FDA”) for use of suprachoroidal CLS-TA for the treatment of
macular edema associated with non-infectious uveitis by the end of
2018. The company is also conducting two ongoing Phase 3
trials of suprachoroidal CLS-TA with an intravitreal anti-VEGF
agent in patients with RVO. In addition, Clearside recently
announced positive topline results from a Phase 2 clinical trial of
suprachoroidal CLS-TA used with Eylea® (aflibercept) in patients
with DME, and is continuing to analyze additional data from the
trial as it becomes available. Clearside is
headquartered in Alpharetta, GA. For more information, please
visit http://www.clearsidebio.com. Follow @clearsidebio on
Twitter and Linkedin.
Cautionary Note Regarding
Forward-Looking Statements
Any statements contained in this press release
that do not describe historical facts may constitute
forward-looking statements as that term is defined in the Private
Securities Litigation Reform Act of 1995. These statements
may be identified by words such as “believe”, “expect”, “may”,
“plan”, “potential”, “will”, and similar expressions, and are based
on Clearside’s current beliefs and expectations. These
forward-looking statements include expectations regarding the
clinical development of Clearside’s product candidates, and the
timing of a potential submission of an NDA with the FDA. These
statements involve risks and uncertainties that could cause actual
results to differ materially from those reflected in such
statements. Risks and uncertainties that may cause actual results
to differ materially include uncertainties inherent in the conduct
of clinical trials, Clearside’s reliance on third parties over
which it may not always have full control, and other risks and
uncertainties that are described in Clearside’s Annual Report on
Form 10-K for the year ended December 31, 2017, filed with the U.S.
Securities and Exchange Commission (“SEC”) on March 16, 2018, and
Clearside’s other Periodic Reports filed with the SEC. Any
forward-looking statements speak only as of the date of this press
release and are based on information available to Clearside as of
the date of this release, and Clearside assumes no obligation to,
and does not intend to, update any forward-looking statements,
whether as a result of new information, future events or
otherwise.
Contacts:
Stephen KilmerInvestor Relations(678)
430-8206stephen.kilmer@clearsidebio.com
Charles DeignanChief Financial Officer(678)
270-4005charlie.deignan@clearsidebio.com
Clearside Biomedical (NASDAQ:CLSD)
Historical Stock Chart
From Aug 2024 to Sep 2024
Clearside Biomedical (NASDAQ:CLSD)
Historical Stock Chart
From Sep 2023 to Sep 2024